Nandrolone Phenylpropionate Genetic
- Diverse genesis cachexia;
- Disorders of protein synthesis after severe trauma, infectious diseases, burns, surgery, and radiotherapy;
- Diverse genesis osteoporosis; progressive muscular dystrophy;
- Aplastic anemia;
- Prevention of myopathy and osteoporosis on the background of glucocorticosteroids treatment;
- Slowed formation of bone callus after trauma.
In the pediatric therapy, the medicine is indicated to treat growth retardation syndrome, Shereshevski-Turner, anorexia, and insufficient food.
Hypersensitivity to the drug, prostate cancer and adenoma, breast cancer in men, breast carcinoma in women with hypercalcemia, ovarian, CPI, severe atherosclerosis, nephritis, nephrotic syndrome, hepatic and renal failure, acute and chronic prostatitis, pregnancy, lactation period until sexual maturation.
Intramuscular injection 1-2 ml once a week. The course of treatment lasts 4-8 weeks. The optimal dose for children is 1-1.5 mg / kg per month; administered preferably from 1/4 to 1/8 of the dose every 7-10 days.
In pituitary dwarfism, the medicine is administered for 2-4 years.
Treatment is carried out on the background of a rich in protein diet.
From the first signs of virilization of patients (deepening of the voice, hirsutism, acne, clitoromegaly) the administration must be discontinued to avoid irreversible changes. A systematic control of lipidemic and cholesterol should be done. The pediatric therapy must be done by an experienced doctor in order to avoid premature epiphyseal bone calcification.
The drug is contraindicated during pregnancy and lactation.
The drug does not affect the ability to drive and use machines.
At the first signs of virilization of patients (voice deepening, hirsutism, acne, clitoromegaly) administration should be stopped to prevent irreversible changes. May occur suppression coagulation plasma factors II, VII, IX and X and increasing prothrombin time. A systematic control the lipidemia and cholesterol. Pediatric Use should be made by an experienced specialist to avoid premature epiphyseal bone calcification.
Women - virilization symptoms, inhibition of ovarian function, menstrual disorders, hypercalcemia.
Men: in the prepubertal period - virilization symptoms, skin hyperpigmentation idiopathic withholding or growth suppression (calcification of epiphyseal zones responsible for tubular bones growth); during postpuberty - bladder irritation, gynecomastia, priapism; in the elderly - hypertrophy and / or prostatic carcinoma.
In men and women - the progression of atherosclerosis, peripheral edema, impaired liver function with jaundice, changes in blood count, bone pain sockets, hypo-coagulation with a tendency to hemorrhage.
Call for emergency help if an overdose situation happened.